There is a rapidly growing population of immunocompromised organ transplant recipients. These patients are at risk of a large variety of infections that have significant consequences on mortality, graft dysfunction, and graft loss. The diagnosis and treatment of these infections are facilitated by an understanding of the preoperative, perioperative, and postoperative risk factors; the typical pathogens; and their characteristic time of presentation. On the basis of these factors, we put forth an algorithm for diagnosing and treating suspected infections in solid organ transplant recipients.
2007Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1997-2006. In: UNOS;URREA, eds. Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation. Rockville, MD: UNOS;2006, 2.
2.
Jamil B., Nicholls K., Becker GJ, Walker RGImpact of acute rejection therapy on infections and malignancies in renal transplant recipients. Transplantation. 1999 ;68: 1597-1603.
3.
Singh N.The current management of infectious diseases in the liver transplant recipient . Clin Liver Dis. 2000;4: 657-673, ix.
4.
Snydman DRInfection in solid organ transplantation. Transpl Infect Dis . 1999;1:21-28.
5.
Cueto G., Trigo P., Arata A., et al. Evaluation of prognostic factors for early infection in liver transplantation. Transplant Proc. 1999;31:3061-3062.
6.
Singh N.Fungal infections in the recipients of solid organ transplantation. Infect Dis Clin North Am.2003;17:113-134, viii.
7.
Baldi A., Mourad M., Malaise J., Squifflet JPLow urinary tract infections in simultaneous pancreas and kidney transplantation: comparison between bladder and enteric drainage of exocrine secretions. Transplant Proc. 1995;27:3116-3117.
8.
Tomikawa S., Ichikawa N., Kikuchi K., et al. Major infectious complications as a risk factor in kidney transplantation . Transplant Proc. 1998;30:3127-3129.
9.
Bassetti M., Salvalaggio PR, Topal J., et al. Incidence, timing and site of infections among pancreas transplant recipients. J Hosp Infect. 2004;56:184-190.
10.
Hagerty JA, Ortiz J., Reich D., Manzarbeitia C.Fungal infections in solid organ transplant patients. Surg Infect (Larchmt). 2003;4:263-271.
Ricart MJ, Malaise J., Moreno A., Crespo M., Fernandez-Cruz L.Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreaskidney transplantation. Nephrol Dial Transplant. 2005;20(suppl2):ii25-ii32, ii62.
13.
Griffiths P. , Ait-Khaled M., Bearcroft C., et al. Human herpesviruses 6 and 7 as potential pathogens after liver transplant: prospective comparison with the effect of cytomegalovirus. J Med Virol. 1999;59:496-501.
14.
Singh N.Human herpesviruses-6, -7 and -8 in organ transplant recipients. Clin Microbiol Infect. 2000;6: 453-459.
15.
Singh N., Husain S., Carrigan DR, et al. Impact of human herpesvirus-6 on the frequency and severity of recurrent hepatitis C virus hepatitis in liver transplant recipients. Clin Transplant. 2002;16:92-96.
16.
Trofe J., Gaber LW, Stratta RJ, et al. Polyomavirus in kidney and kidney-pancreas transplant recipients . Transpl Infect Dis. 2003;5:21-28.
17.
Kidd I., Clark D., Sabin C., et al. Prospective study of human betaherpesviruses after renal transplantation: association of human herpesvirus 7 and cytomegalovirus co-infection with cytomegalovirus disease and increased rejection. Transplantation. 2000;69(11):2400-2404.
18.
Linhares MM , Gonzalez AM, Trivino T., et al. Simultaneous pancreas-kidney transplantation: infectious complications and microbiological aspects. Transplant Proc. May 2004;36(4):980-981.
19.
Olthoff KM, Merion RM, Ghobrial RM, et al. Outcomes of 385 adult-to-adult living donor liver transplant recipients: a report from the A2ALL Consortium. Ann Surg.2005;242:314-323, discussion 323-325.
20.
Gayowski T. , Marino IR, Singh N., et al. Orthotopic liver transplantation in high-risk patients: risk factors associated with mortality and infectious morbidity. Transplantation. 1998;65:499-504.
21.
Hollenbeak CS, Alfrey EJ, Souba WWThe effect of surgical site infections on outcomes and resource utilization after liver transplantation. Surgery. 2001;130:388-395.
22.
Smets YF, van der Pijl JW, van Dissel JT, Ringers J., de Fijter JW, Lemkes HHInfectious disease complications of simultaneous pancreas kidney transplantation . Nephrol Dial Transplant. 1997;12:764-771.
23.
Hellinger WC , Bonatti H., Yao JD, et al. Risk stratification and targeted antifungal prophylaxis for prevention of aspergillosis and other invasive mold infections after liver transplantation. Liver Transpl. 2005;11:656-662.
24.
Singh N., Chang FY, Gayowski T., Wagener M., Marino IRFever in liver transplant recipients in the intensive care unit. Clin Transplant. 1999;13:504-511.
25.
Giral M., Pascuariello G., Karam G., et al. Acute graft pyelonephritis and long-term kidney allograft outcome . Kidney Int. 2002;61:1880-1886.
26.
Introduction to the guidelines. Am J Transplant.2004;4(suppl 10):6-9.
27.
Stafford RE , Weigelt JASurgical infections in the critically ill . Curr Opin Crit Care. 2002;8:449-452.
28.
Schechter S. , Eisenstat TE, Oliver GC, Rubin RJ, Salvati EPComputerized tomographic scan-guided drainage of intra-abdominal abscesses. Preoperative and postoperative modalities in colon and rectal surgery. Dis Colon Rectum.1994;37:984-988.
29.
Stratta RJ, Shokouh-Amiri MH, Egidi MF, et al. A prospective comparison of simultaneous kidney-pancreas transplantation with systemic-enteric versus portal-enteric drainage. Ann Surg. 2001;233:740-751.
30.
Patel R.Infections in recipients of kidney transplants. Infect Dis Clin North Am. 2001;15:901-952, xi.
31.
Kim RD, Oreopoulos DG, Qiu K., et al. Impact of mode of dialysis on intra-abdominal infection after simultaneous pancreas-kidney transplantation. Transplantation . 2005;80:339-343.
32.
Batiuk TD, Bodziak KA, Goldman M.Infectious disease prophylaxis in renal transplant patients: a survey of US transplant centers. Clin Transplant. 2002;16:1-8.
33.
Screening of donor and recipient prior to solid organ transplantation . Am J Transplant. 2004;4(suppl 10): 10-20.
34.
Zibari GB, Lipka J., Zizzi H., Abreo KD, Jacobbi L., McDonald JCThe use of contaminated donor organs in transplantation. Clin Transplant. 2000;14(4 Pt 2): 397-400.
35.
Singh N., Wannstedt C., Keyes L., Wagener MM, Cacciarelli TVWho among cytomegalovirus-seropositive liver transplant recipients is at risk for cytomegalovirus infection? Liver Transpl. 2005;11:700-704.
36.
McLaughlin K., Sandhu S., Wu C., Muirhead N., Hollomby D., Jevnikar A.Transplanting kidneys from CMV-seropositive donors to CMV-seronegative recipients is not associated with poorer renal allograft function or survival. Nephrol Dial Transplant. 2005;20:176-180.
37.
Cytomegalovirus. Am J Transplant. 2004;4(suppl 10): 51-58.
38.
Feng S., Buell JF, Cherikh WS, et al. Organ donors with positive viral serology or malignancy: risk of disease transmission by transplantation. Transplantation . 2002;74:1657-1663.
39.
Iwamoto M., Jernigan DB, Guasch A., et al. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med. 2003;348:2196-2203.
40.
Srinivasan A. , Burton EC, Kuehnert MJ, et al, for the Rabies in Transplant Recipients Investigation Team.Transmission of rabies virus from an organ donor to four transplant recipients. N Engl J Med.2005;352:1103-1111.
41.
Multiply resistant Gram-positive bacteria. Am J Transplant. 2004;4(suppl 10):31-36.
42.
Gouvea EF, Branco RC, Monteiro RC, et al. Outcome of infections caused by multiple drug-resistant bacteria in liver transplant recipients. Transplant Proc. 2004;36: 958-960.
43.
Multiply antibiotic-resistant gram-negative bacteria. Am J Transplant. 2004;4(suppl 10):21-24.
44.
Singh N.Impact of current transplantation practices on the changing epidemiology of infections in transplant recipients. Lancet Infect Dis. 2003;3:156-161.
45.
Eggimann P. , Pittet D.Infection control in the ICU. Chest. 2001;120:2059-2093.
46.
Legionella. Am J Transplant. 2004;4(suppl 10):25-27.
47.
Clostridium difficile. Am J Transplant. 2004;4(suppl 10): 28-30.
48.
Nocardia infections. Am J Transplant. 2004;4(suppl 10): 47-50.
49.
Orsenigo E. , Florina P., Cristallo M., et al. Outcome of simultaneous kidney pancreas transplantation: a single center analysis. Transplant Proc . 2004;36:1519-1523.
50.
Newell KA, Bruce DS, Cronin DC, et al. Comparison of pancreas transplantation with portal venous and enteric exocrine drainage to the standard technique utilizing bladder drainage of exocrine secretions. Transplantation. 1996 ;62:1353-1356.
51.
Kuo PC, Johnson LB, Schweitzer EJ, Bartlett STSimultaneous pancreas/kidney transplantation-a comparison of enteric and bladder drainage of exocrine pancreatic secretions. Transplantation . 1997;63:238-243.
52.
Lo A., Stratta RJ, Hathaway DK, et al. Long-term outcomes in simultaneous kidney-pancreas transplant recipients with portal-enteric versus systemic-bladder drainage. Am J Kidney Dis. 2001;38:132-143.
53.
Pearson TC, Santamaria PJ, Routenberg KL, et al. Drainage of the exocrine pancreas in clinical transplantation: comparison of bladder versus enteric drainage in a consecutive series. Clin Transplant. 1997;11:201-205.
Miemois-Foley J., Paunio M., Lyytikainen O., Salmela K.Bacteremia among kidney transplant recipients: a case-control study of risk factors and short-term outcomes. Scand J Infect Dis.2000;32:69-73.
56.
Fungal infections. Am J Transplant. 2004;4(suppl 10): 110-134.
57.
Paya CVPrevention of fungal infection in transplantation. Transpl Infect Dis. 2002;4(suppl 3):46-51.
Cornely O., Maertens J., Winston D., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med.2007 ;356:348-359.
60.
Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356:335-347.
61.
Mora-Duarte J., Betts R., Rotstein C., et al, for the Caspofungin Invasive Candidiasis Study Group.Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med.2002;347:2020-2029.
62.
Singh N.The changing face of invasive aspergillosis in liver transplant recipients . Liver Transpl. 2002;8:1071-1072.
63.
Scotter JM, Campbell P., Anderson TP, Murdoch DR, Chambers ST, Patton WNComparison of PCR-ELISA and galactomannan detection for the diagnosis of invasive aspergillosis. Pathology. 2005;37:246-253.
64.
Shah RM, Miller W. Jr.Pulmonary complications of transplantation: radiographic considerations. Clin Chest Med. 2005;26:545-560, v.
65.
Pereira CN, Del Nero G., Lacaz CS, Machado CMThe contribution of galactomannan detection in the diagnosis of invasive aspergillosis in bone marrow transplant recipients. Mycopathologia. 2005;159:487-493.
66.
Mattei D., Rapezzi D., Mordini N., et al. False-positive Aspergillus galactomannan enzyme-linked immunosorbent assay results in vivo during amoxicillin-clavulanic acid treatment. J Clin Microbiol. 2004;42: 5362-5363.
67.
Pazos C., Ponton J., Del Palacio A.Contribution of (1->3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan . J Clin Microbiol. 2005;43:299-305.
68.
Herbrecht R. , Denning DW, Patterson TF, et al, for the Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group.Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med.2002;347:408-415.
69.
Pneumocystis jiroveci (formerly Pneumocystis carinii). Am J Transplant. 2004;4(suppl 10):135-141.
70.
Jimenez C., Lumbreras C., Aguado JM, et al. Successful treatment of mucor infection after liver or pancreaskidney transplantation. Transplantation. 2002;73:476-480.
71.
Singh N., Wannstedt C., Keyes L., Wagener MM, Gayowski T., Cacciarelli TVIndirect outcomes associated with cytomegalovirus (opportunistic infections, hepatitis C virus sequelae, and mortality) in liver-transplant recipients with the use of preemptive therapy for 13 years. Transplantation . 2005;79:1428-1434.
72.
Snydman DREpidemiology of infections after solid-organ transplantation. Clin Infect Dis. 2001;33(suppl 1): S5-S8.
73.
Other herpesviruses: HHV-6,HHV-7,HHV-8,HSV-1 and -2, VZV. Am J Transplant. 2004;4(suppl 10):66-71.
74.
Rogers J., Rohal S., Carrigan D., et al. Human herpesvirus-6 in liver transplant recipients: role in pathogenesis of fungal infections, neurologic complications, and outcome. Transplantation. 2000;69:2566-2573.
75.
Epstein-Barr virus and lymphoproliferative disorders after transplantation. Am J Transplant. 2004;4(suppl 10):59-65.
76.
Randhawa P. , Vats A., Shapiro R.Monitoring for polyomavirus BK and JC in urine: comparison of quantitative polymerase chain reaction with urine cytology. Transplantation. 2005;79:984-986.
77.
Randhawa P. , Uhrmacher J., Pasculle W., et al. A comparative study of BK and JC virus infections in organ transplant recipients. J Med Virol. 2005;77:238-243.
78.
Hirsch H., Brennan D., Drachenberg C., et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation . 2005;79:1277-1286.
79.
Lipshutz GS , Mahanty H., Feng S., et al. BKV in simultaneous pancreas-kidney transplant recipients: a leading cause of renal graft loss in first 2 years post-transplant. Am J Transplant. 2005;5:366-373.
80.
Singh N.Impact of current transplantation practices on the changing epidemiology of infections in transplant recipients. Lancet Infect Dis. 2003;3:156-161.
